Crycision Completes Pre-A Round of Investment, Developing Innovative Screening Platform of Nanobodies

According to iyiou.com, Chinese biotech company Crycision has completed its Pre-A round of financing from Dynamic Balance Investment.

Crycision is a Nanjing-based CRO company focusing on the technology of membrane proteins. Its core technology platforms cover gene editing, membrane preparation, structural biology, screening of biological macromolecules and antibody design based on the structure, engaging in the development and modification of nanobodies targeting G protein-coupled receptors (GPCR).

Dr. Tan Jingquan, the founder of Crycision, said that the proceeds of this round would be used to establish an innovative screening platform of nanobodies. Currently, there are few domestic enterprises focusing on the research and development of nanobodies, and those enterprises with the ability and focus on the research and development of membrane proteins such as GPCR are even rarer. Crycision has a high technical advantage at present and is expected to become the leading enterprise in this field.

Since its establishment in 2018, Crycision has obtained three rounds of financing from CAS Star, Ralph Investment and Dynamic Balance Investment, with the total amount over ten million yuan.

Crycision hopes to create an advanced technology platform focusing on the early development of antibodies through innovation and cooperation, to provide high-quality services and products for the global biomedical industry.

Dynamic Balance Investment is a core subsidiary of Jiangning Technology Venture Capital. The company manages 17 venture capital funds with a total amount of 7.5 billion yuan, and 18 industrial funds with a total amount of 17 billion yuan. 

Dynamic Balance Investment has invested in more than 100 investment enterprises, covering angel round, VC, PE. It focuses on investments in the biomedical, TMT, clean energy and new material industries.